Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
- Status
- Not yet recruitingResults none
- Why it is watched
- non-weight indication: liver, nutrition
- Who it enrolls
- age 18 Years to no upper limit; excludes diabetes; no BMI minimum stated; conditions: Metabolic Associated Fatty Liver Disease; Metabolic Associated-dysfunction Steatohepatitis (MASH); Obesity
- Interventions
- semaglutide; Diet
- Conditions
- Metabolic Associated Fatty Liver Disease; Metabolic Associated-dysfunction Steatohepatitis (MASH); Obesity
- Phase and size
- NA · 120 participants
- Dates
- Start 2025-01
Primary completion 2026-05 - Sponsor
- Institut universitaire de cardiologie et de pneumologie de Québec, University Laval (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Liver SteatosisFrom enrollment to the end of the clinical trial at 12 months (for 4 visits)
- Liver StiffnessFrom enrollment to the end of the clinical trial at 12 months (for 4 visits)
02Eligibility
Who can take part
Inclusion Criteria: * Body mass index between 30 and 50 kg/m2; * Stade 2 or 3 (S2 or S3) hepatic steatosis with or without liver fibrosis. Exclusion Criteria: * Type 1 diabetes diagnosis; * Alcohol consumption exceeding recommendations \[\>140 g/week (women) and \>210 g/week (men)\]; * Known chronic hepatic disease non-steatotic at the entry of the study (Wilson's disease, hemochromatosis, alpha-1-antitrypsin deficiency, viral hepatitis, auto-immune hepatitis, etc.); * Pharmacological treatment targeting obesity active or ended in the last 3 months; * Bariatric surgery; * Gastro-intestinal pathologies (GI cancers, IBD, etc.); * Capsulated probiotics consumption; * Antibiotic treatment in the last 3 months; * Pregnancy; * Cirrhosis diagnosis (hepatic decompensation).
03Change log
Registry changes
No changes recorded since the trial was added.